Home Featured Page 97

Featured

Latest

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

PT440 – Coming Back to Stillness, Microdosing and Adaptogens, and What...

Opening Critical Periods with Psychedelics

Vital 2024: Informational Session and Q&A

reMind Psychedelics Business Forum

Optimi Health Granted Amendment to Dealer’s Licence by Health Canada to...

atai Life Sciences to Participate in Upcoming September Investor Conferences

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to...

PT439 – Introducing Hyphae Leaks: Not Your Average Psychedelic Podcast

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD...

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine)...

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

PT440 – Coming Back to Stillness, Microdosing and Adaptogens, and What...

Opening Critical Periods with Psychedelics

Vital 2024: Informational Session and Q&A

reMind Psychedelics Business Forum

Optimi Health Granted Amendment to Dealer’s Licence by Health Canada to...

atai Life Sciences to Participate in Upcoming September Investor Conferences

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to...

PT439 – Introducing Hyphae Leaks: Not Your Average Psychedelic Podcast

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD...

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine)...

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY